SGCB and sickle cell disease: Olinciguat, another sGC stimulator, which is currently in phase 2 clinical development for use in patients with sickle cell anemia (NCT03285178) (Zimmer et al., 2020), not only reduces blood pressure in humans and in hypertensive and normotensive rats but also successfully reduces inflammatory mechanisms in TNF-stimulated mice (Buys et al., 2018; Zimmer et al., 2020).